Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells $32,217.15 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson sold 503 shares of Halozyme Therapeutics stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total transaction of $32,217.15. Following the sale, the director now directly owns 33,108 shares of the company’s stock, valued at $2,120,567.40. This trade represents a 1.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Jeffrey William Henderson also recently made the following trade(s):

• On Monday, March 3rd, Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $58.69, for a total value of $293,450.00.
• On Monday, February 3rd, Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $56.30, for a total value of $281,500.00.
• On Monday, January 6th, Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $50.01, for a total value of $500,100.00.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $63.02 on Thursday. The company has a market cap of $7.79 billion, a price-to-earnings ratio of 18.37, a PEG ratio of 0.42 and a beta of 1.32. The business has a 50 day moving average price of $59.62 and a 200 day moving average price of $54.90. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a twelve month low of $37.73 and a twelve month high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.02. The company had revenue of $298.01 million during the quarter, compared to analysts’ expectations of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in HALO. Lansforsakringar Fondforvaltning AB publ acquired a new stake in Halozyme Therapeutics during the fourth quarter worth about $426,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Halozyme Therapeutics in the 4th quarter worth approximately $10,032,000. Heck Capital Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the 4th quarter worth approximately $29,000. Armis Advisers LLC bought a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $295,000. Finally, GF Fund Management CO. LTD. acquired a new position in shares of Halozyme Therapeutics in the fourth quarter valued at $128,000. Institutional investors own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Piper Sandler lifted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. Wells Fargo & Company reduced their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Benchmark reissued a “buy” rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $62.78.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.